Advertisement
Advertisement

ASND

ASND logo

Ascendis Pharma A/S Ordinary Share

252.99
USD
Sponsored
+1.04
+0.41%
Aug 25, 15:57 UTC -4
Closed
exchange

Pre-Market

254.00

+1.01
+0.40%

Ascendis Pharma A/S Ordinary Share Profile

About

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark.

Info & Links

CEO

Jan M�ller Mikkelsen

Headquarters

TUBORG BOULEVARD 12
HELLERUP, G7 2900, DENMARK

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.ascendispharma.com

Auditor

Deloitte Statsautoriseret Revisionspartnerselskab

Share holders

--

Employees

1,189

Ascendis Pharma A/S Ordinary Share Statistics

Valuation Measures

Market Capitalization2

16.66B

Enterprise Value

16.24B

Enterprise Value/EBITDA(ttm)

50.55

Price to Earnings Ratio(ttm)

140.72

Price to Sales(ttm)

12.94

Price to Book(mrq)

9.46

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

91.14%

Operating Margin(ttm)

12.35%

Profit Margin(ttm)

68.07%

Return on Equity(ttm)

32.54%

Return on Invested Capital(ttm)

27.54%

Return on Assets(ttm)

7.71%

Income Statement

Revenue(ttm)

1.21B

Revenue Per Share(ttm)

--

Gross Profit(ttm)

1.11B

EBITDA(ttm)3

321.29M

Net Income Available to Common(ttm)

863.02M

Diluted EPS(ttm)

12.89

Share Statistics

Beta (5Y Monthly)

0.39

52-Week Change

32.89%

S&P 500 52-Week Change

19.04%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

--

Dividend Yield

0.00%

Float4

37.43M

% Held by Insiders

40.00%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

944.41M

Total Cash Per Share(mrq)

--

Total Debt(mrq)

523.30M

Total Debt/Equity(mrq)

31.33%

Current Ratio(mrq)

2.99%

Quick Ratio(mrq)

2.32%

Book Value Per Share(mrq)

25.43

Cash Flow

Operating Cash Flow Per Share(ytd)

4.66

Free Cash Flow(ytd)

305.81M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement